Octanoylcarnitine
Introduction
Section titled “Introduction”Octanoylcarnitine (C8-carnitine) is a type of acylcarnitine, a molecule formed when a fatty acid is linked to carnitine. Carnitine plays a critical role in cellular metabolism by facilitating the transport of fatty acids into the mitochondria, the cell’s energy-producing organelles, for a process called beta-oxidation. Octanoylcarnitine specifically represents an eight-carbon (medium-chain) fatty acid bound to carnitine.
Biological Basis
Section titled “Biological Basis”The primary biological function of octanoylcarnitine revolves around mitochondrial fatty acid beta-oxidation. Fatty acids, including medium-chain ones like octanoic acid, are bound to free carnitine for transport into the mitochondria.[1] Once inside, enzymes such as Medium-Chain Acyl-Coenzyme A Dehydrogenase (MCAD) initiate their breakdown. Studies have shown that genetic variants, such as the intronic SNP rs11161510 located in the MCAD gene, are strongly associated with the levels of medium-chain acylcarnitines. [1] This association highlights MCAD’s direct role in processing these molecules. Research indicates that individuals who are minor allele homozygotes for rs11161510 may have a reduced enzymatic turnover for these reactions, impacting the metabolism of medium-chain acylcarnitines. [1]
Clinical Relevance
Section titled “Clinical Relevance”The levels of octanoylcarnitine in the blood can serve as an important biomarker for metabolic health, particularly for disorders affecting fatty acid oxidation. Elevated levels of octanoylcarnitine can suggest a deficiency inMCAD activity, a condition known as MCAD deficiency. This is one of the most common inborn errors of metabolism, where the body struggles to break down medium-chain fatty acids, especially during periods of fasting or increased energy demand. Early detection of MCAD deficiency is crucial for preventing severe health complications.
Social Importance
Section titled “Social Importance”Understanding the genetic and metabolic factors influencing octanoylcarnitine levels holds significant social importance, particularly in public health screening programs. Newborn screening often includes testing for acylcarnitine profiles, allowing for the early identification ofMCADdeficiency and other metabolic disorders. Prompt diagnosis enables timely medical intervention and dietary management, which can dramatically improve the prognosis and quality of life for affected children. Furthermore, research into genetically determined metabotypes, such as those impacting acylcarnitine metabolism, contributes to a broader understanding of how genetic variations interact with environmental factors like nutrition and lifestyle to influence susceptibility to common multifactorial diseases.[1] This knowledge supports the development of personalized medicine strategies and targeted public health initiatives.
Limitations
Section titled “Limitations”Methodological and Statistical Constraints
Section titled “Methodological and Statistical Constraints”The genetic research on octanoylcarnitine levels is subject to several methodological and statistical constraints that necessitate careful interpretation of findings. A significant challenge in genome-wide association studies (GWAS) is the potential for false-positive associations, particularly when results have not been consistently replicated across independent cohorts[2]. [3]While some studies demonstrate robust power to detect genetic effects explaining a substantial proportion of phenotypic variation, they may lack the statistical power to identify more modest associations, thereby potentially overlooking numerous variants with smaller, yet cumulatively impactful, effects on octanoylcarnitine levels[2]. [4] Furthermore, the reliance on genotype imputation to enhance marker coverage, although common, introduces a degree of uncertainty, with reported error rates that can influence the accuracy of the derived association signals [5]. [6]
The integration of data through meta-analysis, while crucial for increasing statistical power, also brings challenges related to heterogeneity among contributing studies. Despite the application of genomic control corrections to manage inflation of test statistics, variations in study-specific genotyping quality control, analytical pipelines, and underlying population structures can still impact the consistency and generalizability of pooled results [5]. [7]This underscores the importance of replication in an independent population as the “gold standard” for validating novel genetic associations with metabolites like octanoylcarnitine.[1]
Generalizability and Phenotypic Characterization
Section titled “Generalizability and Phenotypic Characterization”A notable limitation in the current understanding of octanoylcarnitine genetics arises from the demographic composition of the study populations. Many foundational GWAS cohorts are predominantly comprised of individuals of European ancestry, often within middle-aged to elderly age ranges[2], [3], [8]. [9] This demographic homogeneity restricts the direct generalizability of genetic findings to younger individuals or populations with diverse ethnic and racial backgrounds, where genetic predispositions, environmental exposures, and gene-environment interactions may substantially differ [2]. [3] Moreover, the timing of DNA sample collection in some studies, typically later in life, may introduce survival bias, potentially skewing observed genetic associations by underrepresenting individuals who did not survive to later examinations. [2]
The phenotypic characterization of octanoylcarnitine, while employing advanced technologies, also poses interpretational complexities. Although targeted quantitative metabolomics platforms, such as electrospray ionization (ESI) tandem mass spectrometry (MS/MS), enable precise measurements of acylcarnitines, the extensive adjustment of these measurements for numerous covariates like age, sex, and various health conditions is common[1], [5], [8]. [9]While these adjustments are essential for mitigating confounding, they can influence the magnitude and interpretation of observed genetic effect sizes, making direct comparisons across studies, particularly those employing differing adjustment strategies, more intricate. The use of proxy markers for some traits in certain studies also highlights the need for direct and comprehensive phenotyping to fully elucidate the specific genetic influences on metabolites such as octanoylcarnitine.[3]
Environmental Confounders and Remaining Knowledge Gaps
Section titled “Environmental Confounders and Remaining Knowledge Gaps”Current genetic investigations into octanoylcarnitine have primarily focused on identifying direct genetic associations, with limited exploration of gene-environment interactions. Genetic influences on complex traits can be highly context-dependent, implying that environmental factors such as diet, lifestyle, and co-morbidities can significantly modify the expression of genetic susceptibility.[4] The absence of comprehensive analyses of gene-environment interactions represents a critical knowledge gap, as such interactions could account for a substantial portion of unexplained phenotypic variance and reveal genetic effects that are only observable under specific environmental conditions. [4]
Furthermore, despite considerable progress in GWAS, a notable fraction of the heritability for complex traits, including metabolite levels, often remains unaccounted for, a phenomenon referred to as “missing heritability.” This suggests that numerous genetic influences, potentially involving rare variants, structural variations, or complex epistatic interactions, are yet to be discovered. Moving forward, a key challenge involves the functional validation of identified genetic associations, deciphering the precise biological mechanisms through which these variants impact octanoylcarnitine levels, and integrating these findings within broader metabolic pathways to fully elucidate the biological significance of these genetic discoveries.[2]
Variants
Section titled “Variants”The _ABCC1_gene, also known as Multidrug Resistance-associated Protein 1 (MRP1), encodes a crucial transmembrane protein involved in the ATP-dependent efflux of a diverse array of substrates from cells. Its primary physiological function includes protecting cells from harmful xenobiotics, mediating detoxification processes, and transporting certain endogenous metabolites.[10] This broad specificity means that _ABCC1_ plays a significant role in drug disposition and the overall maintenance of cellular homeostasis. [11]
The variant *rs2062541 *is a single nucleotide polymorphism (SNP) located within the_ABCC1_ gene. Such genetic variations can influence gene activity by altering protein expression levels, affecting protein stability, or changing the substrate binding affinity and transport efficiency of the resulting MRP1 protein. Consequently, a variant like *rs2062541 * could lead to modified _ABCC1_ transporter function, thereby impacting the cellular handling and systemic distribution of its various substrates. [12]
One important class of endogenous metabolites that could be influenced by _ABCC1_function are acylcarnitines, such as octanoylcarnitine (C8:0-carnitine). Octanoylcarnitine is a medium-chain acylcarnitine, which are critical intermediates in the beta-oxidation of fatty acids, a process essential for energy production within mitochondria.[10] Although _ABCC1_ is not directly involved in the beta-oxidation pathway itself, its role as a broad-spectrum transporter means that altered activity due to variants like *rs2062541 * could affect the efflux or intracellular concentrations of these metabolites, thereby indirectly influencing fatty acid metabolism and overall metabolic health. [13]
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs145024038 rs2185152 rs61622554 | ACADM | hexanoylcarnitine measurement octanoylcarnitine measurement Cis-4-decenoyl carnitine measurement decanoylcarnitine measurement acylcarnitine measurement |
| rs12091720 rs7550949 rs7552404 | SLC44A5 - ACADM | decanoylcarnitine measurement hexanoylcarnitine measurement octanoylcarnitine measurement cis-4-decenoate (10:1n6) measurement Cis-4-decenoyl carnitine measurement |
| rs17843966 rs67481496 rs1235904433 | ETFDH | blood protein amount protein measurement octanoylcarnitine measurement decanoylcarnitine measurement dodecanoylcarnitine measurement |
| rs55936281 | PPID - FNIP2 | octanoylcarnitine measurement Cis-4-decenoyl carnitine measurement X-11540 measurement glutarylcarnitine (C5-DC) measurement |
| rs17843929 | PPID | nonanoylcarnitine (C9) measurement carnitine measurement peptidyl-prolyl cis-trans isomerase D measurement octanoylcarnitine measurement decanoylcarnitine measurement |
| rs8396 | PPID, ETFDH | metabolite measurement serum metabolite level cerebrospinal fluid composition attribute, isovalerylcarnitine (C5) measurement carnitine measurement peptidyl-prolyl cis-trans isomerase D measurement |
| rs60782127 rs924135 rs2062541 | ABCC1 | BMI-adjusted waist circumference health trait body height octanoylcarnitine measurement cys-gly, oxidized measurement |
| rs12401729 rs2172507 | MSH4 | octanoylcarnitine measurement |
| rs77979447 | ASB17 - ST6GALNAC3 | octanoylcarnitine measurement |
| rs148910542 | LHX8 | octanoylcarnitine measurement hexanoylcarnitine measurement nonanoylcarnitine (C9) measurement |
Nature and Classification
Section titled “Nature and Classification”Octanoylcarnitine is classified as an acylcarnitine, an endogenous metabolite naturally present in human serum. This compound belongs to a broader category of small molecules that are integral to the metabolic state of an organism. In detailed metabolomic profiling, octanoylcarnitine is identified as one of 29 specific acylcarnitines measured within a comprehensive panel that also includes various other endogenous molecules, such as sugar molecules, biogenic amines, and amino acids.[10] Its inclusion in such panels underscores its significance as a specific component reflecting metabolic processes.
Measurement and Analytical Approaches
Section titled “Measurement and Analytical Approaches”The quantification of octanoylcarnitine levels in scientific research relies on advanced targeted quantitative metabolomics platforms. Specifically, the determination of its fasting serum concentrations is achieved through electrospray ionization (ESI) tandem mass spectrometry (MS/MS).[10] This precise operational definition of measurement ensures high sensitivity and accuracy for identifying and quantifying this metabolite within the complex biological matrix of serum. The use of fasting serum samples represents a critical research criterion, establishing a standardized baseline for metabolic assessment across study participants.
Scientific Relevance and Context
Section titled “Scientific Relevance and Context”Octanoylcarnitine serves as a key biomarker in genome-wide association studies (GWAS) focused on profiling metabolites in human serum. Its levels are treated as quantitative traits, enabling researchers to investigate the genetic underpinnings of metabolic variations and their potential associations with health outcomes.[10]By analyzing the variability in octanoylcarnitine concentrations and correlating them with genetic variants, these studies contribute to a deeper understanding of metabolic pathways and the identification of genetic influences on metabolic traits. This conceptual framework positions octanoylcarnitine as an important indicator for exploring metabolic health and disease mechanisms.
Biological Background
Section titled “Biological Background”Octanoylcarnitine and Mitochondrial Fatty Acid Metabolism
Section titled “Octanoylcarnitine and Mitochondrial Fatty Acid Metabolism”Octanoylcarnitine (C8) is a medium-chain acylcarnitine, a class of metabolites crucial for fatty acid processing within cells. Fatty acids, which serve as a significant energy source, must be transported into the mitochondria for beta-oxidation, a process where they are broken down to produce energy. This transport is facilitated by binding fatty acids to free carnitine, forming acylcarnitines.[14] Once inside the mitochondria, enzymes like medium-chain acyl-Coenzyme A dehydrogenase (MCAD) and short-chain acyl-Coenzyme A dehydrogenase (SCAD) initiate the beta-oxidation pathway. These enzymes are specific to the length of the fatty acid chain they process, with MCADprimarily acting on medium-chain fatty acids. Octanoylcarnitine, being a medium-chain acylcarnitine, functions as an indirect substrate forMCAD. [14] Genetic variations, such as the intronic SNP rs11161510 in the MCADgene, can significantly impact the enzyme’s activity, leading to altered concentrations of specific acylcarnitines, including octanoylcarnitine, and influencing overall metabolic flux.[14]
Genetic Regulation of Lipid Pathways
Section titled “Genetic Regulation of Lipid Pathways”Genetic mechanisms play a profound role in orchestrating lipid metabolism, with variations in specific genes influencing the levels of various lipids and metabolites, including acylcarnitines. For instance, polymorphisms in genes encoding acyl-CoA dehydrogenases, such as MCAD, can lead to reduced enzymatic turnover, resulting in higher concentrations of the enzyme’s substrates (longer-chain fatty acids/acylcarnitines) and lower concentrations of its products (shorter-chain fatty acids/acylcarnitines). [14]This highlights how single nucleotide polymorphisms (SNPs) can directly alter metabolic profiles, creating distinct “metabotypes”.[14] The FADS1 and FADS2 gene cluster also contains common genetic variants and reconstructed haplotypes that are associated with the fatty acid composition in phospholipids, further illustrating the genetic influence on lipid components. [15]
Beyond fatty acid oxidation, other genes are critical for broader lipid homeostasis. Variations in HMGCR, which encodes 3-hydroxy-3-methylglutaryl-CoA reductase, a rate-limiting enzyme in cholesterol synthesis, can affect alternative splicing of its mRNA, thereby influencing LDL-cholesterol levels. [16] Similarly, genes like ANGPTL3 and ANGPTL4 are known regulators of lipid metabolism, with ANGPTL4 variations specifically reducing triglycerides and increasing HDL. [17] The transcription factor HNF4A is also essential, controlling hepatic gene expression and lipid homeostasis, demonstrating the intricate regulatory networks governing these pathways. [18]
Systemic Lipid Homeostasis and Disease Implications
Section titled “Systemic Lipid Homeostasis and Disease Implications”Disruptions in lipid metabolism, often influenced by genetic predispositions, have systemic consequences that contribute to various pathophysiological processes, particularly cardiovascular diseases. Abnormal plasma concentrations of lipids such as low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides define dyslipidemia, a major risk factor for coronary artery disease (CAD).[6] Genome-wide association studies have identified numerous genetic loci that influence these lipid traits, demonstrating the polygenic nature of dyslipidemia. [19]
The interplay between genetic variants and environmental factors, such as diet and lifestyle, shapes an individual’s “metabotype” and their susceptibility to common multifactorial diseases.[14] For instance, a null mutation in APOC3has been shown to confer a favorable plasma lipid profile and apparent cardioprotection, illustrating how specific genetic alterations can mitigate disease risk.[20] Furthermore, conditions like lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes highlight the direct link between specific enzyme dysfunctions and severe disruptions in lipid metabolism. [21]Understanding these genetic influences on metabolites like octanoylcarnitine provides valuable insights into the underlying mechanisms of metabolic disorders and their broader impact on organ systems.
Cellular Transport and Regulatory Networks
Section titled “Cellular Transport and Regulatory Networks”The efficient transport of molecules across cellular membranes and the intricate coordination of metabolic pathways are fundamental to cellular function. Carnitine, a key biomolecule, serves as a shuttle for fatty acids, enabling their entry into the mitochondrial matrix where beta-oxidation takes place.[14]This cellular function is vital for energy production, especially during periods of high energy demand. The specific acylcarnitine forms, such as octanoylcarnitine, represent the fatty acids undergoing this transport and metabolic processing, making them indicators of mitochondrial function and fatty acid flux.[14]
Beyond transport, complex regulatory networks control lipid and energy metabolism. Transcription factors like SREBP-2 (sterol regulatory element-binding protein 2) play a crucial role in regulating genes involved in cholesterol and fatty acid synthesis, linking isoprenoid and adenosylcobalamin metabolism. [22] Other cellular components, such as Erlin-1 and Erlin-2, contribute to the organization of lipid-raft-like domains within the endoplasmic reticulum, influencing membrane dynamics and signaling. [23] These molecular and cellular pathways are interconnected, ensuring the maintenance of metabolic homeostasis and responding to physiological demands.
Pathways and Mechanisms
Section titled “Pathways and Mechanisms”Role in Mitochondrial Fatty Acid Oxidation
Section titled “Role in Mitochondrial Fatty Acid Oxidation”Octanoylcarnitine, a medium-chain acylcarnitine, serves a crucial function in the cellular energy metabolism by facilitating the transport of medium-chain fatty acids into the mitochondrial matrix. This transport is a prerequisite for beta-oxidation, the catabolic process that breaks down fatty acids to generate acetyl-CoA for the citric acid cycle and ultimately ATP production.[1]The binding of fatty acids to free carnitine is an essential step that allows them to cross the inner mitochondrial membrane, ensuring a continuous supply of substrates for energy generation, particularly during periods of increased metabolic demand or nutrient deprivation. This pathway represents a key aspect of energy metabolism and fatty acid catabolism.
Genetic Influence on Metabolic Flux
Section titled “Genetic Influence on Metabolic Flux”The efficiency of mitochondrial fatty acid oxidation is subject to genetic regulation, impacting the levels of circulating acylcarnitines. A specific polymorphism, rs11161510 , located within the MCAD (medium-chain acyl-Coenzyme A dehydrogenase) gene, has been significantly associated with variations in the concentrations of medium-chain acylcarnitines, including octanoylcarnitine.[1] MCAD is an enzyme that catalyzes the initial, rate-limiting step of medium-chain fatty acid beta-oxidation. Studies indicate that individuals who are homozygous for the minor allele of rs11161510 exhibit higher levels of longer-chain fatty acid substrates and commensurately lower levels of their shorter-chain products, suggesting a reduced enzymatic turnover and altered metabolic flux through this critical pathway. [1]
Pathway Dysregulation and Clinical Implications
Section titled “Pathway Dysregulation and Clinical Implications”Dysregulation within the medium-chain fatty acid oxidation pathway, often stemming from genetic variations that impair MCADactivity, can lead to the accumulation of medium-chain acylcarnitines such as octanoylcarnitine. This buildup signifies a metabolic bottleneck, where the body’s capacity to process and utilize these fatty acids for energy is compromised.[1]While the provided research does not detail specific disease outcomes directly linked to octanoylcarnitine accumulation, such disruptions in fundamental metabolic processes can profoundly affect energy homeostasis. These alterations could contribute to the underlying susceptibility for various metabolic conditions, highlighting the broader biological significance of maintaining precise flux control within these catabolic pathways.
References
Section titled “References”[1] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”PLoS Genet, vol. 4, no. 11, 2008, p. e1000282.
[2] Benjamin, E. J., et al. “Genome-wide association with select biomarker traits in the Framingham Heart Study.” BMC Medical Genetics, vol. 8, suppl. 1, 2007, S12.
[3] Hwang, S. J., et al. “A genome-wide association for kidney function and endocrine-related traits in the NHLBI’s Framingham Heart Study.” BMC Medical Genetics, vol. 8, suppl. 1, 2007, S11.
[4] Vasan, R. S., et al. “Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.”BMC Medical Genetics, vol. 8, suppl. 1, 2007, S2.
[5] Yuan, X., et al. “Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.” The American Journal of Human Genetics, vol. 83, no. 6, 2008, pp. 721-728.
[6] Willer CJ, et al. “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.” Nat Genet. 2008; 40(2):161-169.
[7] Aulchenko, Y. S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nature Genetics, vol. 41, no. 1, 2008, pp. 47-55.
[8] Melzer, D., et al. “A genome-wide association study identifies protein quantitative trait loci (pQTLs).” PLoS Genetics, vol. 4, no. 5, 2008, e1000072.
[9] Kathiresan S, et al. “Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans.” Nat Genet. 2008; 40(2):189-197.
[10] Gieger C, “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.”
[11] Wallace C, “Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia.”
[12] Sabatti C, “Genome-wide association analysis of metabolic traits in a birth cohort from a founder population.”
[13] Willer CJ, “Newly identified loci that influence lipid concentrations and risk of coronary artery disease.”
[14] Gieger C, et al. “Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum.” PLoS Genet. 2009; 5(2):e1000282.
[15] Schaeffer L, et al. “Common genetic variants of the FADS1 FADS2 gene cluster and their reconstructed haplotypes are associated with the fatty acid composition in phospholipids.” Hum Mol Genet. 2006; 15(11):1745-1756.
[16] Burkhardt R, et al. “Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13.” Arterioscler Thromb Vasc Biol. 2008; 28(12):2071-2077.
[17] Koishi R, et al. “Angptl3 regulates lipid metabolism in mice.” Nat Genet. 2002; 30(2):151-157.
[18] Hayhurst GP, et al. “Hepatocyte nuclear factor 4alpha (nuclear receptor 2A1) is essential for maintenance of hepatic gene expression and lipid homeostasis.” Mol Cell Biol. 2001; 21(4):1393-1403.
[19] Kathiresan S, et al. “Common variants at 30 loci contribute to polygenic dyslipidemia.” Nat Genet. 2009; 41(5):561-569.
[20] Pollin TI, et al. “A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection.” Science. 2008; 322(5906):1092-1095.
[21] Kuivenhoven JA, et al. “The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes.” J Lipid Res. 1997; 38(2):191-205.
[22] Murphy C, et al. “Regulation by SREBP-2 defines a potential link between isoprenoid and adenosylcobalamin metabolism.” Biochem Biophys Res Commun. 2007; 355(2):359-364.
[23] Browman DT, Resek ME, Zajchowski LD, et al. “Erlin-1 and erlin-2 are novel members of the prohibitin family of proteins that define lipid-raft-like domains of the ER.” J Cell Sci. 2006; 119(Pt 15):3149-3160.